https://scholars.lib.ntu.edu.tw/handle/123456789/551041
標題: | Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan | 作者: | CHEN-HUA LIU TUNG-HUNG SU CHUN-JEN LIU PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2020 | 出版社: | Elsevier B.V. | 卷: | 119 | 期: | 12 | 起(迄)頁: | 1871-1875 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Despite the excellent antiviral effects of direct acting antivirals (DAAs) for hepatitis C virus (HCV) infection with subsequent decrease of morbidity and mortality, a small proportion (5%) of the treated patients do not respond to first-line DAAs and have persistent viremia. Rescue therapy for patients with DAA failures is thus mandatory from both clinical and public health perspectives. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), a fixed-dose pangenotypic rescue agent, has been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for retreating HCV patients who fail prior DAA therapies. However, this agent has not been licensed by health authorities of Taiwan. Herein we reported two cases who successfully cleared HCV by using SOF/VEL/VOX plus ribavirin (RBV) after virologic failures to first-line pangenotypic SOF/VEL. Furthermore, we discussed the current unmet medical needs and clinical implications of SOF/VEL/VOX on the perspectives of HCV elimination in Taiwan. ? 2020 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086436887&doi=10.1016%2fj.jfma.2020.06.013&partnerID=40&md5=4d450ad72c7f79cce553028bfb75aae8 https://scholars.lib.ntu.edu.tw/handle/123456789/551041 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2020.06.013 | SDG/關鍵字: | ribavirin; robatrol; sofosbuvir plus velpatasvir plus voxilaprevir; virus RNA; 2 amino 2 methylpropionic acid; antivirus agent; carbamic acid derivative; cyclopropane derivative; fused heterocyclic rings; leucine; macrocyclic lactam; proline; quinoxaline derivative; ribavirin; sofosbuvir; sulfonamide; velpatasvir; voxilaprevir; adult; antiviral activity; Article; case report; chronic hepatitis C; clinical article; Hepatitis B virus; human; Human immunodeficiency virus infection; male; medical history; middle aged; mixed infection; Taiwan; treatment duration; viral clearance; chronic hepatitis C; drug combination; genotype; sustained virologic response; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。